Literature DB >> 16282155

Behçet's disease.

Adriana A Bonfioli1, Fernando Orefice.   

Abstract

Behçet's disease is a chronic, relapsing vasculitis that can affect most organ systems. The prevalence varies geographically, and the disease is more common in countries along the ancient Silk Road, including Italy, Turkey, Israel, Saudi Arabia, Iran, China, Korea and Japan. Behçet's is more common in men than in women, and typically affects young adults. The classic finding in Behçet's patients is the presence of recurrent mucocutaneous ulcers, and oral aphthous ulcerations are usually the initial symptom. Other manifestations include genital ulcers, skin lesions, vascular, neurological, articular, and ocular disease. The disease can affect the anterior and/or posterior segments of the eye, and the main manifestations include iridocyclitis, hypopyon, mild to moderate vitreitis, retinal vasculitis and occlusion, optic disc hyperemia, and macular edema. There is no pathognomonic laboratory test in Behçet's disease, and the diagnosis is based in systemic and ocular clinical findings. Treatment of ocular Behçet is based in corticosteroids and immunosuppressive agents, to suppress acute inflammation and reduce its recurrence frequency. Ocular lesions may improve with immunosuppressive therapy, but usually are not fully reversible, and generally progress over time. The prognosis of anterior uveitis is usually good, but patients with posterior lesions tend to have some degree of visual loss, even with adequate treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282155     DOI: 10.1080/08820530500231953

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  21 in total

1.  Visfatin levels in Behcet's disease.

Authors:  Hatice Sezen; Seydi Okumus; Yavuz Pehlivan; Ismail Dilli; Mehmet Tarakcioğlu; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

2.  Capillary dropout after photodynamic therapy in a patient with Bechet's disease.

Authors:  Ke-Hung Chien; Yun-Hsiang Chang; Ching-Long Chen; Jiann-Torng Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-12       Impact factor: 3.117

3.  Evaluation of the fungiform papillae number in Behçet's disease.

Authors:  Gökçen Akçiçek; Nihal Avcu; Serdar Uysal
Journal:  Clin Oral Investig       Date:  2014-08-06       Impact factor: 3.573

4.  Anticardiolipin antibodies in patients with Behcet's disease.

Authors:  Maja Zivkovic; Marko Zlatanovic; Gordana Zlatanovic; Jasmina Djordjevic-Jocic; Sonja Cekic
Journal:  Bosn J Basic Med Sci       Date:  2011-02       Impact factor: 3.363

Review 5.  Neuro-Behçet's syndrome: differential diagnosis and management.

Authors:  Erdal Diri; Louis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

6.  Behçet's Disease: an Insight from a Cardiologist's Point of View.

Authors:  Giuseppe Cocco; Armen Yuri Gasparyan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

7.  Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells.

Authors:  C Wang; Z Ye; A Kijlstra; Y Zhou; P Yang
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

8.  The association of the PTPN22 620W polymorphism with Behcet's disease.

Authors:  Vijay Baranathan; Miles R Stanford; Robert W Vaughan; Elli Kondeatis; Elizabeth Graham; Farida Fortune; Wafa Madanat; Charlie Kanawati; Marwen Ghabra; Philip I Murray; Graham R Wallace
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

9.  Decreased microRNA-155 in Behcet's disease leads to defective control of autophagy thereby stimulating excessive proinflammatory cytokine production.

Authors:  Liang Liang; Qingyun Zhou; Lujia Feng
Journal:  Arthritis Res Ther       Date:  2021-05-06       Impact factor: 5.156

Review 10.  Intraocular inflammation: its causes and investigations.

Authors:  Claire Hooper; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.